Abnex have a range of innovative projects and technologies available for licensing and commercialization. We aim to serve through new partnerships or technology transfers by leveraging our talents and assets. We have developed a number of technologies and biopharmaceutical projects that subsequently are licensed to our development collaborators. The out-licensing projects include 4 humanized monoclonal antibodies (1 “naked” and 3 as antibody-drug conjugates), 2 monoclonal antibodies (immune checkpoint inhibitors) for immunotherapy and an innovative platform for multi-specific antibody production. When you collaborate with us, you are getting much more than a high quality project. You gain access to our array of technical resources, including the scientific know-how. Our dedicated team of scientists and professionals are available to quickly address your needs. Our team have a thorough understanding of the latest tools and advances in antibody drug R&D.